RESUMO
Heparin induced thrombocytopenia (HIT) is a serious adverse drug reaction caused by transient antibodies against platelet factor 4 (PF4)/heparin complexes, resulting in platelet activation and potentially fatal arterial and/or venous thrombosis. Most cases of HIT respond to cessation of heparin and administration of an alternative non-heparin anticoagulant, but there are cases of persisting HIT, defined as thrombocytopenia due to platelet activation/consumption for greater than seven days despite standard therapy. These patients remain at high risk for thrombotic events, which may result in limb-loss and mortality. Intravenous immunoglobulin (IVIg) has been proposed as an adjunct therapy for these refractory cases based on its ability to saturate FcγRIIa receptors on platelets, thus preventing HIT antibody binding and platelet activation. We describe 2 cases of persisting HIT (strongly positive antigen and functional assays, and persisting thrombocytopenia >7 days) with rapid clinical response to IVIg. We performed in-vitro experiments to support IVIg response. Healthy donor platelets (1â¯×â¯10e6) were treated with PF4 (3.75⯵g/mL) for 20â¯min followed by 1-hour incubation with patients' sera. Platelet activation with and without addition of IVIg (levels equivalent to those reached in a patient after treatment with 2â¯gm/Kg) was evaluated in the PF4-dependent P-selectin expression assay (PEA). A significantly decreased platelet activation was demonstrated after the addition of IVIg to both patient samples, which correlated well with the rapid clinical response that each patient experienced. Thus, our study supports the use of IVIg as an adjunct therapy for persisting HIT.
Assuntos
Heparina/efeitos adversos , Imunoglobulinas Intravenosas/uso terapêutico , Trombocitopenia/induzido quimicamente , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
Seismic source and wave propagation studies contribute to understanding structure, transport, fracture mechanics, mass balance, and other processes within glaciers and surrounding environments. Glaciogenic seismic waves readily couple with the bulk Earth, and can be recorded by seismographs deployed at local to global ranges. Although the fracturing, ablating, melting, and/or highly irregular environment of active glaciers can be highly unstable and hazardous, informative seismic measurements can commonly be made at stable proximal ice or rock sites. Seismology also contributes more broadly to emerging studies of elastic and gravity wave coupling between the atmosphere, oceans, solid Earth, and cryosphere, and recent scientific and technical advances have produced glaciological/seismological collaborations across a broad range of scales and processes. This importantly includes improved insight into the responses of cryospheric systems to changing climate and other environmental conditions. Here, we review relevant fundamental physics and glaciology, and provide a broad review of the current state of glacial seismology and its rapidly evolving future directions.
Assuntos
Anticorpos/sangue , Anticoagulantes/efeitos adversos , Anticoagulantes/imunologia , Heparina/efeitos adversos , Heparina/imunologia , Técnicas Imunoenzimáticas , Fator Plaquetário 4/imunologia , Trombocitopenia/diagnóstico , Humanos , Técnicas Imunoenzimáticas/normas , Valor Preditivo dos Testes , Sensibilidade e Especificidade , Trombocitopenia/sangue , Trombocitopenia/induzido quimicamente , Trombocitopenia/imunologia , Fatores de TempoRESUMO
Drug-induced immune thrombocytopenia (DITP) can be triggered by a wide range of medications. Although many cases of DITP are mild, some are characterized by life-threatening bleeding symptoms. The pathogenesis of DITP is complex, in that at least six different mechanisms have been proposed by which drug-induced antibodies can promote platelet destruction. It is possible in many cases to identify antibodies that react with platelets in the presence of the sensitizing drug, but the required testing is technically demanding and not widely available. Therefore, a decision on whether to discontinue an implicated medication in a patient suspected of having DITP must be made on clinical grounds. An algorithm is available that can be helpful in assessing the likelihood that a particular drug caused thrombocytopenia, but the most important aspects of patient management are a high index of suspicion and a careful history of drug exposure in an individual who presents with acute, often severe thrombocytopenia of unknown etiology. How drugs induce platelet-reactive antibodies and how, once formed, the antibodies cause platelet destruction following exposure to the drug is poorly understood. Further studies to address these issues and characterize more completely the range of drugs and drug metabolites that can cause DITP are needed.
Assuntos
Trombocitopenia/diagnóstico , Trombocitopenia/terapia , Autoanticorpos/biossíntese , Humanos , Incidência , Trombocitopenia/induzido quimicamente , Trombocitopenia/imunologiaRESUMO
Herein we describe a novel animal model for examining the survival and function of human platelets following their circulation in non-obese diabetic/severe combined immunodeficient mice. Resting human platelets in platelet-rich plasma are introduced into the retro-orbital plexus, where they are absorbed with high efficiency and circulate for up to 2 days, comprising 10-20% of total circulating platelets. During this period of time, the human platelets can be exposed to a number of biochemical and immunochemical reagents, including novel antithrombotic compounds, or human antiplatelet antibodies that have been implicated in platelet destruction, activation or clearance. Platelets can also be subjected to a variety of storage conditions before infusion, and their relative survival and function following storage and circulation compared. The ability to evaluate in living mice the in vivo function and survival of circulating human platelets may prove valuable for determining mechanisms of antibody-mediated platelet passivation, and aid in the development of novel antiplatelet therapeutics.
Assuntos
Plaquetas/citologia , Sobrevivência Celular , Inibidores da Agregação Plaquetária/farmacologia , Animais , Plaquetas/imunologia , Humanos , Camundongos , Camundongos Endogâmicos NOD , Camundongos SCID , Trombocitopenia/imunologiaAssuntos
Inibidores da Agregação Plaquetária/efeitos adversos , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/antagonistas & inibidores , Trombocitopenia/etiologia , Abciximab , Anticorpos Monoclonais/efeitos adversos , Autoanticorpos/sangue , Eptifibatida , Humanos , Fragmentos Fab das Imunoglobulinas/efeitos adversos , Peptídeos/efeitos adversos , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/imunologia , Trombocitopenia/sangue , Tirofibana , Tirosina/efeitos adversos , Tirosina/análogos & derivadosRESUMO
Heparin, employed clinically for more than 50 years, is still a widely used anticoagulant. Unfortunately, some patients given this agent develop thrombocytopenia and thrombosis. Because this side effect can have catastrophic consequences, it is imperative that all clinicians caring for patients who receive heparin have at least a basic understanding of its pathogenesis, diagnosis, and management.
Assuntos
Anticoagulantes/efeitos adversos , Heparina/efeitos adversos , Trombocitopenia/patologia , Trombose/patologia , Anticoagulantes/administração & dosagem , Feminino , Heparina/administração & dosagem , Humanos , Masculino , Trombocitopenia/sangue , Trombocitopenia/induzido quimicamente , Trombose/sangue , Trombose/induzido quimicamenteAssuntos
Anticorpos/fisiologia , Heparina/imunologia , Ativação Plaquetária/imunologia , Trombocitopenia/etiologia , Trombose/etiologia , Ensaio de Imunoadsorção Enzimática , Heparina/efeitos adversos , Humanos , Ativação Plaquetária/efeitos dos fármacos , Fator Plaquetário 4/análise , Fator Plaquetário 4/imunologia , Valor Preditivo dos Testes , Serotonina/metabolismo , Trombocitopenia/imunologia , Trombose/imunologia , Fatores de TempoRESUMO
Assays measuring platelet-associated immunoglobulin G (PAIgG), while highly sensitive, lack specificity in diagnosing autoimmune thrombocytopenia (AITP). We prospectively evaluated a new commercially available glycoprotein (GP)-specific assay, the PakAuto (GTI, Brookfield, WI), for its clinical usefulness in distinguishing immune from nonimmune thrombocytopenia (TP), in 216 patients with autoimmune TP (both primary "idiopathic" and "secondary") and 46 patients with TP due to other causes. This assay is designed to detect both platelet-associated (direct assay) and plasma (indirect assay) antiplatelet antibodies specific for GPs IIb/IIIa, Ib/IX, and Ia/IIa. The mean platelet counts of the immune (79 +/- 7 x 10(9)/L) and nonimmune groups (78 +/- 7 x 10(9)/L), were similar (P=0.95). The direct assay was positive in 114/216 patients with AITP (53%), and 13/46 with nonimmune TP (28%). Among the AITP group, the majority (61%) of patients with positive test results had autoantibodies reactive against all three GP targets. The sensitivity, specificity, positive, and negative predictive values for the direct PakAuto were 53%, 72%, 90%, and 24%, respectively, comparable to previously published experience of GP-specific assays. However, in some cases of TP due to nonimmune cause, the PakAuto was highly specific. Only 3 of 22 patients with gestational and 1 of 8 with familial/congenital TP had a positive direct assay, indicating that the test may be particularly useful for excluding an immune etiology for TP in certain patient subgroups.
Assuntos
Autoanticorpos/análise , Técnicas Imunoenzimáticas/métodos , Glicoproteínas da Membrana de Plaquetas/imunologia , Púrpura Trombocitopênica Idiopática/diagnóstico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Especificidade de Anticorpos , Autoanticorpos/imunologia , Plaquetas/imunologia , Criança , Pré-Escolar , Diagnóstico Diferencial , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Contagem de Plaquetas , Valor Preditivo dos Testes , Estudos Prospectivos , Púrpura Trombocitopênica Idiopática/sangue , Púrpura Trombocitopênica Idiopática/imunologia , Sensibilidade e EspecificidadeAssuntos
Anticorpos Monoclonais/imunologia , Ensaio de Imunoadsorção Enzimática , Kit de Reagentes para Diagnóstico , Animais , Anticorpos Monoclonais/sangue , Ensaio de Imunoadsorção Enzimática/métodos , Reações Falso-Positivas , Humanos , Camundongos , Kit de Reagentes para Diagnóstico/normas , Reprodutibilidade dos TestesRESUMO
The purpose of this study was to test the hypothesis that residues critical for ligand- and temperature-induced clustering of integrin alphaIIbbeta3 are present on its extracellular domain. Sucrose density gradient sedimentation was used to examine the effects of ligand-mimetic peptides and physiological temperature on the oligomeric state of a soluble recombinant ectodomain variant of the alphaIIbbeta3 integrin, alphaIIbDelta962beta3Delta692, and its full-length counterpart. Both the ectodomain construct, isolated from High Five insect cell culture supernatants, and alphaIIbbeta3, isolated from human blood platelets, exhibited similar weight-average sedimentation coefficients at 23 degrees C, in the absence and presence of the ligand-mimetic peptide eptifibatide. These observations indicate that alphaIIbbeta3's ectodomain exhibits a similar extended conformation in both its free and ligand-bound states. Oligomerization was examined by incubation of both alphaIIbDelta962beta3Delta692 and full-length receptors at 37 degrees C, in the presence or absence of ligand-mimetic. Minimal oligomerization was observed with alphaIIbDelta962beta3Delta692. In contrast, full-length alphaIIbbeta3 exhibited substantial temperature-induced increases in its distribution of sedimenting species, indicative of thermal aggregation. These observations suggest that optimum oligomerization requires the participation of the integrin's transmembrane and cytoplasmic regions. In vivo, clustering of ligand-bound integrins may enhance signaling by increasing the local concentration of intracellular integrin-associated proteins.
Assuntos
Complexo Glicoproteico GPIIb-IIIa de Plaquetas/química , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/metabolismo , Animais , Plaquetas/metabolismo , Linhagem Celular , Centrifugação com Gradiente de Concentração , Cromatografia de Afinidade , Insetos , Ligantes , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/genética , Desnaturação Proteica , Estrutura Quaternária de Proteína , Estrutura Terciária de Proteína , Solubilidade , Soluções , TemperaturaRESUMO
BACKGROUND: Acute thrombocytopenia is a recognized side-effect of treatment with the fibrinogen receptor antagonist, abciximab, a chimeric (human/mouse) Fab fragment. The etiology of this complication is not fully understood. Generally, abciximab-induced thrombocytopenia occurs within a few hours of starting treatment with the drug. We have characterized a group of 13 patients who first developed thrombocytopenia 3-6 days after abciximab was discontinued. OBJECTIVE: To characterize clinical and serological aspects of this newly recognized clinical entity. PATIENTS AND METHODS: Clinical information was obtained from attending physicians and review of hospital records. Antibodies reactive with abciximab-coated platelets were characterized by flow cytometry. RESULTS: In each patient, IgG and/or IgM antibodies reactive with abciximab-coated platelets were identified. These antibodies could be distinguished from similar antibodies present in many normal persons by two criteria-they were relatively resistant to inhibition by normal Fab fragments, and they reacted preferentially with platelets coated with 7E3, the murine monoclonal antibody from which peptide sequences in abciximab are derived. Antibodies with these characteristics were not found in pretreatment serum from three of the thrombocytopenic patients or in patients given abciximab who did not develop thrombocytopenia. CONCLUSIONS: 'Delayed thrombocytopenia' after treatment with abciximab is caused by antibodies produced in response to the drug. These antibodies may be specific for murine peptide sequences in abciximab but could recognize other target epitopes on abciximab-coated platelets. Physicians administering abciximab should be aware of this potential complication of treatment, which usually occurs after discharge from hospital.
Assuntos
Anticorpos Monoclonais/efeitos adversos , Anticorpos Monoclonais/imunologia , Fragmentos Fab das Imunoglobulinas/efeitos adversos , Fragmentos Fab das Imunoglobulinas/imunologia , Trombocitopenia/induzido quimicamente , Abciximab , Idoso , Animais , Anticorpos/sangue , Anticorpos Heterófilos/sangue , Anticorpos Monoclonais/metabolismo , Formação de Anticorpos , Plaquetas/metabolismo , Hipersensibilidade a Drogas , Feminino , Citometria de Fluxo , Humanos , Fragmentos Fab das Imunoglobulinas/metabolismo , Masculino , Camundongos , Pessoa de Meia-Idade , Estudos Retrospectivos , Trombocitopenia/imunologiaRESUMO
BACKGROUND: Maternal antibodies that cause neonatal alloimmune thrombocytopenia are commonly identified by solid-phase assays that detect the causative antibodies on the basis of their reactions with specific PLT glycoproteins. Two cases of severe neonatal alloimmune thrombocytopenia caused by maternal antibodies specific for human PLT antigen 3a (HPA-3a [Baka]) that failed to give the expected reactions in some solid-phase assays were recently encountered. STUDY DESIGN AND METHODS: PLT-reactive antibodies were characterized by three different solid-phase assays and by flow cytometry. RESULTS: The two maternal antibodies gave negative reactions in the antigen capture ELISA, modified antigen capture ELISA, and MoAb immobilization of PLT antigens tests but reacted strongly in flow cytometry with intact PLTs that were HPA-3a+. Other sera samples specific for HPA-3a reacted equally well in all assays. CONCLUSIONS: The two antibodies appear to recognize an epitope on the HPA-3a+ form of glycoprotein IIb that is lost when PLTs are solubilized in detergent, as required for solid-phase assays. The diagnosis was made in these cases because no HLA antibodies were present, allowing an HPA-3a-specific reaction to be identified with intact PLTs as targets. Such antibodies are likely to be overlooked when HLA antibodies are also present.
Assuntos
Antígenos de Plaquetas Humanas/imunologia , Plaquetas/imunologia , Isoanticorpos/sangue , Trombocitopenia/etiologia , Adulto , Epitopos , Feminino , Citometria de Fluxo , Humanos , Recém-Nascido , Isoanticorpos/imunologia , Trombocitopenia/imunologiaRESUMO
BACKGROUND: TRALI is usually an immunologic reaction to WBC antibodies in infused plasma and ranks second only to ABO mismatch as a cause of transfusion-associated death. Implicated donors are usually multiparous women (>/=3 pregnancies). STUDY DESIGN AND METHODS: Two fatal cases of TRALI were evaluated by reviewing clinical and laboratory findings and characterizing alloantibodies present in donor plasma. Investigation for WBC antibodies was by lymphocytotoxicity (LCT), FlowPRA (FlowPRA, One Lambda, Inc.) and granulocyte immunofluorescence and agglutination assays. Patient 1 was a 62-year-old man with chronic T-cell lymphocytic leukemia, and Patient 2 was a 54-year-old woman undergoing a cadaveric kidney transplant. Both patients developed acute respiratory distress and hypotension during (Patient 1) and approximately 30 minutes after (Patient 2) transfusion. Fulminant pulmonary edema ensued in both cases necessitating mechanical ventilation and both patients died within 24 hours of the onset of respiratory complications. RESULTS: The donors of the implicated blood components were women with a history of two pregnancies but no blood transfusions. Weak apparently panreactive granulocyte antibodies were detected with flow cytometry. However, in the granulocyte agglutination test, strong antibodies specific for human neutrophil antigen (HNA)-3a (5b) were identified in both donors. CONCLUSION: It is concluded that female blood donors with only two previous pregnancies can form clinically important granulocyte-reactive alloantibodies leading to fatal TRALI reactions in recipients. The sometimes devastating consequences of TRALI should prompt the development of strategies to prevent or reduce its incidence. Further research is warranted to investigate recipient and donor factors responsible for TRALI, including whether 5b (HNA-3a) alloantibodies are especially prone to cause severe reactions, and to better characterize the HNA-3a (5b) antigen, particularly at the molecular level.
Assuntos
Anticorpos/imunologia , Granulócitos/fisiologia , Pneumopatias/etiologia , Neutrófilos/imunologia , Reação Transfusional , Aglutinação , Doadores de Sangue , Evolução Fatal , Feminino , Humanos , Isoantígenos/imunologia , Pneumopatias/imunologia , Masculino , Pessoa de Meia-IdadeRESUMO
We report here the first case of severe immune thrombocytopenia induced by a second-generation cephalosporin antibiotic, Loracarbef. A 56-year old white female developed acute severe thrombocytopenia associated with acute respiratory symptoms following administration of Loracarbef. She responded to Loracarbef withdrawal and systemic corticosteroid administration. Loracarbef-dependent platelet-reactive antibodies were demonstrable in her serum by flow cytometry.
Assuntos
Cefalosporinas/efeitos adversos , Púrpura Trombocitopênica Idiopática/induzido quimicamente , Autoanticorpos/sangue , Plaquetas/imunologia , Feminino , Citometria de Fluxo , Humanos , Metilprednisolona/uso terapêutico , Pessoa de Meia-Idade , Púrpura Trombocitopênica Idiopática/tratamento farmacológico , Infecções Respiratórias/tratamento farmacológicoRESUMO
Heparin-induced thrombocytopenia (HIT), with or without thrombosis, is a common and often serious complication of heparin therapy. Platelet-activating, heparin-induced antibodies characteristic of HIT are thought to be specific for complexes formed between platelet factor 4 (PF4) and heparin, and such complexes are routinely used for antibody detection. We studied the binding of HIT antibodies to PF4 complexed with heparin fractions of uniform molecular size or linear polyanions other than heparin and found that many compounds other than heparin form complexes with PF4 that are suitable for antibody detection, provided they carry strong negative charges spaced about 0.5 nm apart along the molecular backbone and are of sufficient length to span about 40% of the circumference of the PF4 tetramer. Polyvinyl phosphonate was among the compounds that were equivalent to heparin. Thus neither a polysaccharide chain nor sulfate side groups--the hallmarks of heparin structure--are required for HIT antibody detection. The findings support the view that antibodies associated with HIT are specific for conformational changes that take place in the positively charged PF4 molecule when it reacts with a suitable, linear polyanion.